ES2532124T3 - Medios y procedimientos para el tratamiento de enfermedades tumorales - Google Patents
Medios y procedimientos para el tratamiento de enfermedades tumorales Download PDFInfo
- Publication number
- ES2532124T3 ES2532124T3 ES06818912.5T ES06818912T ES2532124T3 ES 2532124 T3 ES2532124 T3 ES 2532124T3 ES 06818912 T ES06818912 T ES 06818912T ES 2532124 T3 ES2532124 T3 ES 2532124T3
- Authority
- ES
- Spain
- Prior art keywords
- use according
- cells
- antibody construct
- antibody
- bispecific
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05027606 | 2005-12-16 | ||
| EP05027606 | 2005-12-16 | ||
| EP06004144 | 2006-03-01 | ||
| EP06004144 | 2006-03-01 | ||
| PCT/EP2006/011466 WO2007068354A1 (en) | 2005-12-16 | 2006-11-29 | Means and methods for the treatment of tumorous diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2532124T3 true ES2532124T3 (es) | 2015-03-24 |
Family
ID=37944802
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES06818912.5T Active ES2532124T3 (es) | 2005-12-16 | 2006-11-29 | Medios y procedimientos para el tratamiento de enfermedades tumorales |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US8007796B2 (enExample) |
| EP (1) | EP1976886B1 (enExample) |
| JP (2) | JP5442998B2 (enExample) |
| AU (1) | AU2006326727A1 (enExample) |
| CA (1) | CA2633594C (enExample) |
| CY (1) | CY1116041T1 (enExample) |
| DK (1) | DK1976886T3 (enExample) |
| ES (1) | ES2532124T3 (enExample) |
| HR (1) | HRP20150175T1 (enExample) |
| PL (1) | PL1976886T3 (enExample) |
| PT (1) | PT1976886E (enExample) |
| RS (1) | RS53905B1 (enExample) |
| RU (1) | RU2008129080A (enExample) |
| SI (1) | SI1976886T1 (enExample) |
| WO (1) | WO2007068354A1 (enExample) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3136727B2 (ja) | 1992-01-13 | 2001-02-19 | 日本電気株式会社 | 適応フィルタ制御方法 |
| DK1874821T3 (da) | 2005-04-26 | 2013-07-08 | Trion Pharma Gmbh | Kombination af antistoffer med glykokortikoider til behandling af kræft |
| AU2006326727A1 (en) * | 2005-12-16 | 2007-06-21 | Amgen Research (Munich) Gmbh | Means and methods for the treatment of tumorous diseases |
| HRP20140331T1 (hr) | 2006-08-14 | 2014-05-09 | Xencor, Inc. | Optimizirana antitijela usmjerena na cd19 |
| US20110262440A1 (en) | 2008-11-07 | 2011-10-27 | Micromet Ag | Treatment of pediatric acute lymphoblastic leukemia |
| CA2742249C (en) | 2008-11-07 | 2020-07-21 | Micromet Ag | Treatment of acute lymphoblastic leukemia with a cd19xcd3 bispecific single chain antibody |
| SI2493503T2 (sl) * | 2009-10-27 | 2021-04-30 | Amgen Research (Munich) Gmbh | Režim odmerjanja za dajanje cd19xcd3 bispecifičnega protitelesa |
| US8796420B2 (en) | 2009-12-31 | 2014-08-05 | Avidbiotics Corp. | Non-natural MIC proteins |
| US8658765B2 (en) | 2009-12-31 | 2014-02-25 | Avidbiotics Corp. | Non-natural MIC proteins |
| DK2632954T4 (da) | 2010-10-27 | 2021-08-09 | Amgen Res Munich Gmbh | Midler og fremgangsmåder til behandling af dlbcl |
| SMT201700250T1 (it) | 2010-11-10 | 2017-07-18 | Amgen Res Munich Gmbh | Prevenzione di effetti avversi provocati da domini leganti cd3 specifici |
| US9249217B2 (en) | 2010-12-03 | 2016-02-02 | Secretary, DHHS | Bispecific EGFRvIII x CD3 antibody engaging molecules |
| EP2701741B1 (en) | 2011-04-28 | 2020-06-10 | Amgen Research (Munich) GmbH | Dosage regimen for administering a cd19xcd3 bispecific antibody to patients at risk for potential adverse effects |
| US20140004121A1 (en) | 2012-06-27 | 2014-01-02 | Amgen Inc. | Anti-mesothelin binding proteins |
| US9486475B2 (en) | 2013-02-08 | 2016-11-08 | Amgen Research (Munich) Gmbh | PPS for the prevention of potential adverse effects caused by CD3 specific binding domains |
| JO3529B1 (ar) | 2013-02-08 | 2020-07-05 | Amgen Res Munich Gmbh | مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد |
| ES2960807T3 (es) | 2013-10-11 | 2024-03-06 | Us Health | Anticuerpos contra TEM8 y su uso |
| WO2015103549A1 (en) | 2014-01-03 | 2015-07-09 | The United States Of America, As Represented By The Secretary Department Of Health And Human Services | Neutralizing antibodies to hiv-1 env and their use |
| FI3531133T3 (fi) | 2014-05-30 | 2023-11-02 | Amgen Res Munich Gmbh | Prekursori-b-solujen akuutin lymfoblastisen leukemian potilaiden riskiluokittelu |
| EP3875481B1 (en) | 2014-11-14 | 2025-01-22 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Neutralizing antibodies to ebola virus glycoprotein and their use |
| CA3224507A1 (en) | 2014-12-24 | 2016-06-30 | Autolus Limited | Cell co-expressing chimeric antigen receptors binding cd19 and cd22 |
| CA3225013A1 (en) | 2015-02-24 | 2016-09-01 | Bioatla, Llc | Conditionally active proteins |
| WO2016138160A1 (en) | 2015-02-24 | 2016-09-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use |
| PT3271389T (pt) | 2015-03-20 | 2020-05-13 | Us Health | Anticorpos neutralizantes dirigidos contra a gp120 e sua utilização |
| IL319047A (en) | 2015-08-28 | 2025-04-01 | Amunix Operating Inc | Chimeric polypeptide composition and methods for its preparation and use |
| WO2017062748A1 (en) | 2015-10-07 | 2017-04-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Il-7r-alpha specific antibodies for treating acute lymphoblastic leukemia |
| WO2017079479A1 (en) | 2015-11-03 | 2017-05-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human | Neutralizing antibodies to hiv-1 gp41 and their use |
| WO2017192589A1 (en) | 2016-05-02 | 2017-11-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to influenza ha and their use and identification |
| EP3478321A4 (en) | 2016-06-30 | 2020-04-22 | Oncorus, Inc. | Pseudotyped oncolytic viral delivery of therapeutic polypeptides |
| EP3579848B1 (en) | 2017-02-08 | 2024-10-30 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| EP3580235B1 (en) | 2017-02-10 | 2024-05-01 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use |
| JP7685821B2 (ja) | 2017-02-20 | 2025-05-30 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｈｅｒ２、ＮＫＧ２ＤおよびＣＤ１６に結合するタンパク質 |
| JP2021508477A (ja) * | 2017-12-29 | 2021-03-11 | オンコラス， インコーポレイテッド | 治療用ポリペプチドの腫瘍溶解性ウイルス送達 |
| WO2019136029A1 (en) | 2018-01-02 | 2019-07-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to ebola virus glycoprotein and their use |
| MX2020008336A (es) | 2018-02-08 | 2020-09-21 | Dragonfly Therapeutics Inc | Dominios variables de anticuerpos que se dirigen al receptor nkg2d. |
| BR112020015994A2 (pt) | 2018-02-08 | 2020-12-15 | Dragonfly Therapeutics, Inc. | Terapia de combinação do câncer que envolve proteínas de ligação multiespecíficas que ativam células natural killer |
| JP7353576B2 (ja) | 2018-02-20 | 2023-10-02 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｃｄ３３、ｎｋｇ２ｄ、及びｃｄ１６に結合する多重特異性結合タンパク質、ならびにその使用方法 |
| WO2019165122A1 (en) | 2018-02-21 | 2019-08-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to hiv-1 env and their use |
| SG11202101298XA (en) | 2018-08-08 | 2021-03-30 | Dragonfly Therapeutics Inc | Proteins binding nkg2d, cd16 and a tumor-associated antigen |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| EA202190468A1 (ru) | 2018-08-08 | 2021-07-06 | Драгонфлай Терапьютикс, Инк. | Мультиспецифические связывающие белки, которые связывают bcma, nkg2d и cd16, и способы их применения |
| WO2020132214A2 (en) | 2018-12-20 | 2020-06-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Ebola virus glycoprotein-specific monoclonal antibodies and uses thereof |
| US20220204620A1 (en) | 2019-04-30 | 2022-06-30 | Amgen Research (Munich) Gmbh | Means and methods for treating burkitt lymphoma or leukemia |
| EP3962523A2 (en) | 2019-05-03 | 2022-03-09 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use |
| KR20230031981A (ko) | 2019-05-14 | 2023-03-07 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| US20230085439A1 (en) | 2019-05-21 | 2023-03-16 | University Of Georgia Research Foundation, Inc. | Antibodies that bind human metapneumovirus fusion protein and their use |
| JP7489407B2 (ja) | 2019-05-21 | 2024-05-23 | ノバルティス アーゲー | Ｃｄ１９結合分子及びその使用 |
| JP2022539589A (ja) | 2019-07-02 | 2022-09-12 | ザ ユナイテッド ステイツ オブ アメリカ アズ リプリゼンテッド バイ ザ セクレタリー、デパートメント オブ ヘルス アンド ヒューマン サービシーズ | ＥＧＦＲｖＩＩＩと結合するモノクローナル抗体およびその使用 |
| EP4073122A4 (en) | 2019-12-11 | 2024-03-27 | Cullinan Oncology, Inc. | ANTI-CD19 ANTIBODIES AND MULTI-SPECIFIC BINDING PROTEINS |
| EP4073114A4 (en) * | 2019-12-11 | 2024-04-17 | Cullinan Oncology, Inc. | Anti-serum albumin antibodies |
| WO2021150824A1 (en) * | 2020-01-22 | 2021-07-29 | Amgen Research (Munich) Gmbh | Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof |
| JP2023517889A (ja) | 2020-03-10 | 2023-04-27 | マサチューセッツ インスティテュート オブ テクノロジー | ＮＰＭ１ｃ陽性がんの免疫療法のための組成物および方法 |
| AR122018A1 (es) | 2020-05-06 | 2022-08-03 | Dragonfly Therapeutics Inc | Proteínas que se unen a nkg2d, cd16 y clec12a |
| KR20230092863A (ko) | 2020-06-11 | 2023-06-26 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| WO2022132904A1 (en) | 2020-12-17 | 2022-06-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies targeting sars-cov-2 |
| AU2022221297A1 (en) | 2021-02-09 | 2023-08-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Antibodies targeting the spike protein of coronaviruses |
| CA3210753A1 (en) | 2021-02-09 | 2022-08-18 | University Of Georgia Research Foundation, Inc. | Human monoclonal antibodies against pneumococcal antigens |
| CN117222663A (zh) | 2021-03-03 | 2023-12-12 | 蜻蜓疗法股份有限公司 | 使用结合nkg2d、cd16和肿瘤相关抗原的多特异性结合蛋白治疗癌症的方法 |
| WO2023044272A1 (en) | 2021-09-17 | 2023-03-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Synthetic humanized llama nanobody library and use thereof to identify sars-cov-2 neutralizing antibodies |
| JP2025506172A (ja) | 2022-02-10 | 2025-03-07 | ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ | コロナウイルスを広く標的とするヒトモノクローナル抗体 |
| US20250197483A1 (en) | 2022-03-28 | 2025-06-19 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Neutralizing antibodies to hiv-1 env and their use |
| EP4565329A1 (en) | 2022-08-01 | 2025-06-11 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Monoclonal antibodies that bind to the underside of influenza viral neuraminidase |
| WO2024054822A1 (en) | 2022-09-07 | 2024-03-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Engineered sars-cov-2 antibodies with increased neutralization breadth |
| WO2024064826A1 (en) | 2022-09-22 | 2024-03-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use |
| WO2024137381A1 (en) | 2022-12-19 | 2024-06-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Monoclonal antibodies for treating sars-cov-2 infection |
| WO2024138151A1 (en) | 2022-12-22 | 2024-06-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Ebolavirus (sudan and zaire) antibodies from non-human primates and human vaccinees |
| WO2024243355A1 (en) | 2023-05-24 | 2024-11-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies that target the rh5 complex of blood-stage plasmodium falciparum |
| WO2025014896A1 (en) | 2023-07-07 | 2025-01-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Humanized 40h3 antibody |
| WO2025024233A1 (en) | 2023-07-21 | 2025-01-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Bispecific antibodies that broadly target coronaviruses |
| WO2025106427A1 (en) | 2023-11-14 | 2025-05-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing and protective monoclonal antibodies against respiratory syncytial virus (rsv) |
| WO2025117384A1 (en) | 2023-12-01 | 2025-06-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Broadly neutralizing influenza hemagglutinin stem-directed antibodies |
| US20250230251A1 (en) | 2023-12-20 | 2025-07-17 | Bristol-Myers Squibb Company | Antibodies targeting il-18 receptor beta (il-18rb) and related methods |
| WO2025137284A2 (en) | 2023-12-21 | 2025-06-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Broadly neutralizing antibodies against sars-cov-2 and sars-cov variants |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19725586C2 (de) * | 1997-06-17 | 1999-06-24 | Gsf Forschungszentrum Umwelt | Verfahren zur Herstellung von Zellpräparaten zur Immunisierung mittels heterologer intakter bispezifischer und/oder trispezifischer Antikörper |
| WO1999054440A1 (en) * | 1998-04-21 | 1999-10-28 | Micromet Gesellschaft Für Biomedizinische Forschung Mbh | CD19xCD3 SPECIFIC POLYPEPTIDES AND USES THEREOF |
| TW200408407A (en) * | 2001-11-30 | 2004-06-01 | Dana Farber Cancer Inst Inc | Methods and compositions for modulating the immune system and uses thereof |
| WO2005007809A2 (en) * | 2003-05-30 | 2005-01-27 | Alexion Pharmaceuticals, Inc. | Antibodies and fusion proteins that include engineered constant regions |
| RU2005141512A (ru) | 2003-05-31 | 2007-07-20 | Микромет Аг (De) | Фармацевтические композиции, включающие биспецифические анти-cd3, анти-cd19 конструкции антител для лечения расстройств, связанных с b-клетками |
| EP2292664B1 (en) | 2003-10-16 | 2016-11-23 | Amgen Research (Munich) GmbH | Multispecific deimmunized CD3-binders |
| DK1874821T3 (da) | 2005-04-26 | 2013-07-08 | Trion Pharma Gmbh | Kombination af antistoffer med glykokortikoider til behandling af kræft |
| AU2006326727A1 (en) * | 2005-12-16 | 2007-06-21 | Amgen Research (Munich) Gmbh | Means and methods for the treatment of tumorous diseases |
| CA2742249C (en) * | 2008-11-07 | 2020-07-21 | Micromet Ag | Treatment of acute lymphoblastic leukemia with a cd19xcd3 bispecific single chain antibody |
| US20220281997A1 (en) * | 2019-09-27 | 2022-09-08 | Nanjing GenScript Biotech Co., Ltd. | Anti-VHH Domain Antibodies and Use Thereof |
-
2006
- 2006-11-29 AU AU2006326727A patent/AU2006326727A1/en not_active Abandoned
- 2006-11-29 JP JP2008544796A patent/JP5442998B2/ja active Active
- 2006-11-29 DK DK06818912T patent/DK1976886T3/en active
- 2006-11-29 PL PL06818912T patent/PL1976886T3/pl unknown
- 2006-11-29 SI SI200631893T patent/SI1976886T1/sl unknown
- 2006-11-29 ES ES06818912.5T patent/ES2532124T3/es active Active
- 2006-11-29 RS RS20150179A patent/RS53905B1/sr unknown
- 2006-11-29 PT PT06818912T patent/PT1976886E/pt unknown
- 2006-11-29 HR HRP20150175TT patent/HRP20150175T1/hr unknown
- 2006-11-29 CA CA2633594A patent/CA2633594C/en active Active
- 2006-11-29 RU RU2008129080/13A patent/RU2008129080A/ru not_active Application Discontinuation
- 2006-11-29 EP EP06818912.5A patent/EP1976886B1/en active Active
- 2006-11-29 WO PCT/EP2006/011466 patent/WO2007068354A1/en not_active Ceased
- 2006-11-29 US US12/095,951 patent/US8007796B2/en active Active
-
2011
- 2011-08-26 US US13/219,120 patent/US11154617B2/en active Active
-
2013
- 2013-09-26 JP JP2013200055A patent/JP5834056B2/ja active Active
-
2015
- 2015-02-25 CY CY20151100194T patent/CY1116041T1/el unknown
-
2021
- 2021-09-21 US US17/480,504 patent/US20220088196A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| DK1976886T3 (en) | 2015-03-02 |
| WO2007068354A1 (en) | 2007-06-21 |
| EP1976886A1 (en) | 2008-10-08 |
| HK1116202A1 (en) | 2008-12-19 |
| US20090291072A1 (en) | 2009-11-26 |
| AU2006326727A1 (en) | 2007-06-21 |
| EP1976886B1 (en) | 2014-12-17 |
| RS53905B1 (sr) | 2015-08-31 |
| CA2633594A1 (en) | 2007-06-21 |
| JP5834056B2 (ja) | 2015-12-16 |
| HRP20150175T1 (en) | 2015-03-27 |
| US11154617B2 (en) | 2021-10-26 |
| PT1976886E (pt) | 2015-03-09 |
| PL1976886T3 (pl) | 2015-06-30 |
| JP5442998B2 (ja) | 2014-03-19 |
| US8007796B2 (en) | 2011-08-30 |
| CA2633594C (en) | 2021-10-26 |
| RU2008129080A (ru) | 2010-01-27 |
| WO2007068354A8 (en) | 2007-08-09 |
| JP2009519257A (ja) | 2009-05-14 |
| SI1976886T1 (sl) | 2015-03-31 |
| US20220088196A1 (en) | 2022-03-24 |
| JP2014028840A (ja) | 2014-02-13 |
| US20130095103A1 (en) | 2013-04-18 |
| CY1116041T1 (el) | 2017-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2532124T3 (es) | Medios y procedimientos para el tratamiento de enfermedades tumorales | |
| KR102595561B1 (ko) | Pd-1 억제제를 투여함으로써 피부암을 치료하는 방법 | |
| JP7126941B2 (ja) | がんを治療するための抗ｐｄ－１抗体と二重特異性抗ｃｄ２０／抗ｃｄ３抗体の組合せ | |
| US20230203202A1 (en) | Proteins binding nkg2d, cd16 and 5t4 | |
| CN117222663A (zh) | 使用结合nkg2d、cd16和肿瘤相关抗原的多特异性结合蛋白治疗癌症的方法 | |
| CN110536905A (zh) | 用于治疗肺癌的抗pd-1抗体 | |
| CN105636986A (zh) | 包含vegf拮抗剂和抗-ctla-4抗体的组合的方法和组合物 | |
| KR20230093282A (ko) | 폐암에 대한 lag-3 길항제 요법 | |
| JP2023542257A (ja) | 癌の治療のために二重特異性ｔ細胞誘導分子の治療用量を投与する方法 | |
| KR20240099362A (ko) | 혈액암에 대한 lag-3 길항제 요법 | |
| AU2013202375B2 (en) | Means and Methods for the Treatment of Tumorous Diseases | |
| TW202539732A (zh) | 以雙特異性抗muc16×抗cd28抗體與抗pd-1抗體之組合或與雙特異性抗muc16×抗cd3抗體之組合治療復發性卵巢癌及子宮內膜癌之方法 | |
| RU2799529C2 (ru) | Стратегия дозирования, уменьшающая синдром высвобождения цитокинов для биспецифичных антител к cd3/c20 | |
| HK1116202B (en) | Means and methods for the treatment of tumorous diseases | |
| WO2025117869A1 (en) | Methods of treating recurrent ovarian cancer and endometrial cancer with bispecific anti-muc16 x anti-cd28 antibodies in combination with anti-pd-1 antibodies or bispecific anti-muc16 x anti-cd3 antibodies | |
| RU2771759C2 (ru) | Антитела против pd-1 для лечения рака легких | |
| CN118475618A (zh) | 用双特异性抗CD3xMUC16抗体和抗CTLA-4抗体治疗癌症的方法 | |
| KR20230061499A (ko) | Pd-1 저해제 투여에 의한 암 통증 치료 방법 | |
| EA046291B1 (ru) | Способы лечения злокачественного новообразования биспецифическими антителами против cd3xmuc16 и антителами против pd-1 |